Managed Care

 

A Phase II Trial Finds Ixekizumab “Extremely Effective” and Safe for Psoriasis

Kenneth Gordon, Professor of Dermatology at Northwestern University, discusses phase II safety and efficacy studies of the anti–interleukin-17 monoclonal antibody ixekizumab for psoriasis. In a year-long extension of a 12-week trial, ixekizumab was “extremely effective” at sustaining responses, leading to complete clearance in 40% to 50% of patients. The drug was also very well tolerated, with no safety signals that raised concern.

Meetings

4th Partnering With ACOs Summit Los Angeles, CA October 27–28, 2014
PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014
HealthIMPACT Southeast Tampa, FL January 23, 2015